

Special Issue

Molecular Mechanisms and Therapy of Gliomas

Message from the Guest Editor

In recent years, knowledge of the molecular landscape of gliomas has greatly expanded. It has been shown that histologically similar tumors display distinct epigenetic, genetic, transcriptomic, and proteomic features and that the clinical outcome of gliomas can be better predicted by integrating histological and molecular data rather than by histology. This has led to the development of novel glioma classification schemes. Indeed, the latest World Health Organization Classification of gliomas, published in 2021, subdivided gliomas not only on their growth pattern, that is, diffuse or circumscribed, on their histopathological features and on their anatomical location, but also on genetic alterations. In addition, the essential diagnostic criterion for some tumor types is a unique DNA methylation profile. An increasing understanding of the molecular features of gliomas has also led to the identification of novel potential therapeutic targets. This Special Issue aims to collect papers on recent advances in the molecular mechanisms of glioma pathogenesis and progression and on novel therapeutic strategies for these tumors.

Guest Editor

Dr. Valeria Barresi

Department of Diagnostics and Public Health, P.le L.A. Scuro, University of Verona, 37129 Verona, Italy

Deadline for manuscript submissions

closed (31 May 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/170378

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).